Ballicules.com

Vonoprazan

VOQUEZNA

Pronunciation: von-OE-pra-zan (voe-KWEZ-na)

Vonoprazan ballicule: receptor binding, kinetics and half-life diagram
Mechanism of action: Vonoprazan ballicule
Vonoprazan VOQUEZNA mascot mnemonic cartoon
Visual mnemonic: Vonoprazan mascot
“Bono praisin’ faux Quizno”

What it isA potassium-competitive acid blocker (P-CAB) for erosive esophagitis and H. pylori combination therapy.

Why this oneUnlike covalent PPIs, it suppresses acid rapidly, needs no meal timing or acid activation, and holds intragastric pH higher and steadier.

What limits itSustained acid suppression can cause diarrhea, infection and nutrient depletion; review drugs needing gastric acidity for absorption.

Vonoprazan molecular structure (skeletal formula)
Molecular structure: Vonoprazan

FDA label

FDA dosingPopulationStartTargetMax
Healing of erosive esophagitis (and relief of associated heartburn)Adults20 mg QD20 mg QD x 8 weeks20 mg QD
Maintenance of healed erosive esophagitis (and relief of associated heartburn)Adults10 mg QD10 mg QD up to 6 months10 mg QD
Heartburn of non-erosive GERDAdults10 mg QD10 mg QD x 4 weeks10 mg QD
H. pylori infection - triple therapy (with amoxicillin 1,000 mg BID + clarithromycin 500 mg BID)Adults20 mg BID (12 h apart)20 mg BID x 14 days20 mg BID
H. pylori infection - dual therapy (with amoxicillin 1,000 mg TID)Adults20 mg BID20 mg BID x 14 days20 mg BID

Renal eGFR <30 mL/min: EE healing 10 mg QD; H. pylori regimens not recommended. eGFR >=30 and all maintenance-of-EE/NERD dosing: no adjustment

Hepatic Child-Pugh B/C: EE healing 10 mg QD; H. pylori regimens not recommended. Child-Pugh A and all maintenance-of-EE/NERD dosing: no adjustment

Instructions

Available strengths

Contraindications

Cautions

Adverse reactions

Pregnancy No adequate human data; rat fetal abnormalities only at ~130x human exposure; offspring liver injury in rats attributed to lactation exposure; pregnancy registry 1-866-609-1612

Lactation Present in human milk (<0.3% of maternal weight-adjusted dose); infant liver injury seen in rat studies at clinically relevant exposures - weigh benefits against risk

Cost

Vonoprazan (VOQUEZNA)
Strength#/mogeneric $/moCostPlus
10 mgtab30 qdnot offered
20 mgtab30 qdnot offered
NADAC is a voluntary CMS survey of what retail community pharmacies pay for the drugs they stock. Vonoprazan is dispensed outside retail pharmacies, so it rarely appears on surveyed invoices.

NO BOXED WARNINGS

Classes and tags

Clinical profile

Therapeutic safety burden1 / 4
Overdose danger1 / 4
Weight-gain liability0 / 4
Sedation liability0 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk2 / 4

Legacy pregnancy categoryN/A (post-2015 labeling)

Defining liabilityAcid-suppression complications and CYP-mediated interactions

Open Vonoprazan in the interactive console ↗